Selexys Pharmaceuticals Corporation
Oklahoma City
About Selexys Pharmaceuticals Corporation
Selexys Pharmaceuticals Corporation (Selexys) is a privately held company that is developing drugs to treat inflammatory and thrombotic diseases. They are targeting the underlying disease mechanism for these disorders. Their target is the adhesion of white blood cells to sites of inflammation mediated by the binding of two proteins, P-selectin and PSGL-1. The company is in preclinical development of humanized antibodies to P-selectin and PSGL-1 for the treatment of acute and chronic inflammatory and thrombotic disorders. Unregulated inflammatory processes play a major role in the harmful effects of multiple inflammatory disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $74.6M
- Funding stage: M&A
- Last round: Series B (Feb 2015)
- Website: selexys.com
- Phone: (405) 319-8195
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/selexys-pharmaceuticals-corporation-2994593 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.